验证数据展示
经过测试的应用
Positive WB detected in | HGF treated A549 cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Western Blot (WB) | WB : 1:500-1:1000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
WB | See 2 publications below |
产品信息
30737-1-AP targets Phospho-c-Met (Tyr1234/1235) in WB, ELISA applications and shows reactivity with Human samples.
经测试应用 | WB, ELISA Application Description |
文献引用应用 | WB |
经测试反应性 | Human |
文献引用反应性 | human |
免疫原 | Peptide 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | met proto-oncogene (hepatocyte growth factor receptor) |
别名 | AUTS9, c Met, HGF receptor, HGF/SF receptor, HGFR, MET, Proto oncogene c Met, RCCP2, Scatter factor receptor, SF receptor, Tyrosine protein kinase Met |
计算分子量 | 1390 aa, 155 kDa |
观测分子量 | 145 kDa |
GenBank蛋白编号 | BC130420 |
基因名称 | MET |
Gene ID (NCBI) | 4233 |
RRID | AB_3085352 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | P08581 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
c-Met (MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to HGF ligand. The binding of HGF to MET induces MET clustering and phosphorylation of Y1234 and Y1235, followed by phosphorylation of Y1349 and Y1356 in the carboxyl terminal region, to which adaptor molecules associate and transmit signals downstream. (PMID: 28064454)
实验方案
Product Specific Protocols | |
---|---|
WB protocol for Phospho-c-Met (Tyr1234/1235) antibody 30737-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
J Ethnopharmacol Anti-hepatocellular carcinoma activity of Sorbaria sorbifolia by regulating VEGFR and c-Met/apoptotic pathway | ||
Theranostics Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma |